Surendran Chemmenkotil to Join Metropolis Healthcare Limited as Chief Executive Officer, Effective from January 2, 2023
December 09, 2022 at 05:03 am
Share
Mr. Surendran Chemmenkotil to join as the Chief Executive Officer of Metropolis Healthcare Limited. He is a seasoned leader with 34 years of rich and diverse experience across consumer facing companies such as Xerox India Limited and Bharti Airtel Limited. Mr. Surendran will be joining Metropolis after a robust and successful stint as Managing Director & Chief Executive Officer (CEO) of Airtel Networks Ltd, Nigeria, a leading telecommunications
company in Nigeria. He comes with a vast experience across geographies, functions and businesses to his credit. Mr. Surendran began his career as a Customer Engineer at Xerox India Limited and was elevated to the rank of the Head of Outsource and Customer Satisfaction at national level. He then joined Bharti Airtel Limited., in 2003 and has worked across several verticals and in different roles across the country. He was the CEO for Airtel Northeast & Assam Circle and then moved in as CEO for Karnataka circle, which is Airtel's market, heading Mobile, Broadband and Enterprise lines of business between 2013-2015. With this stellar and consistent performance in various roles across geographies within India, Mr. Surendran was selected as the Managing Director & CEO for Airtel Networks, Nigeria which is the biggest market for Airtel Africa. Mr. Surendran will be joining Metropolis Healthcare Limited as CEO, effective from 2nd January 2023. The company believe his rigorous execution skills, keen ability to build strong teams and skill in building consumer services businesses will be critical in building Metropolis 3.0 as a strong and a preferred consumer brand. On the education front, Mr. Surendran holds a Bachelor of Engineering with specialisation in Electronics and Power from Regional Engineering College, Nagpur and MBA from Annamalai University.
Metropolis Healthcare Limited is an India-based company, which is engaged in providing diagnostic services. The Company operates through the pathology services segment. The Company offers a range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. The Company also offers analytical and support services to clinical research organizations for their clinical research projects. Its services include pathology testing services, corporate wellness, lab in hospitals and clinical research services. The Company offers a range of tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. It owns a chain of diagnostic centers across India, South Asia, Africa, and the Middle East. The Company has spread its footprint across 20 Indian states and over 220 cities.